Adam Taich Biography and Net Worth

CFO of 10x Genomics

Adam S. Taich has served as our Chief Financial Officer since August 2024.

Prior to 10x Genomics, Adam was Chief Strategy Officer of Standard BioTools Inc. from January 2024 to July 2024. He previously served as interim Chief Executive Officer of SomaLogic, Inc., a proteomics company, from March 2023 until SomaLogic’s acquisition by Standard BioTools in January 2024. Adam joined SomaLogic as Chief Business Officer in November 2021 and later took on expanded responsibilities as SomaLogic’s Executive Vice President of Life Sciences.

Prior to joining SomaLogic, Adam spent 19 years at ThermoFisher Scientific, a global supplier of scientific instrumentation, reagents and software services. He held various roles including as Vice President & General Manager—Molecular Biology; Vice President—Strategy and Business Development; Vice President & General Manager—Protein and Cell Analysis and Vice President & General Manager—Global Services and Support.

Adam holds a bachelor’s degree in Political Science and Russian from Miami University in Oxford, Ohio.

What is Adam Taich's net worth?: The estimated net worth of Adam Taich is at least $5.40 million as of November 24th, 2025. Mr. Taich owns 297,385 shares of 10x Genomics stock worth more than $5,397,538 as of December 5th. This net worth estimate does not reflect any other investments that Mr. Taich may own. Learn More about Adam Taich's net worth.
How do I contact Adam Taich?: The corporate mailing address for Mr. Taich and other 10x Genomics executives is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. 10x Genomics can also be reached via phone at 925-401-7300 and via email at [email protected]. Learn More on Adam Taich's contact information.
Has Adam Taich been buying or selling shares of 10x Genomics?: In the last ninety days, Adam Taich has sold $225,872.00 of 10x Genomics stock. Most recently, Adam Taich sold 11,888 shares of the business's stock in a transaction on Monday, November 24th. The shares were sold at an average price of $19.00, for a transaction totalling $225,872.00. Following the completion of the sale, the chief financial officer now directly owns 297,385 shares of the company's stock, valued at $5,650,315. Learn More on Adam Taich's trading history.
Who are 10x Genomics' active insiders?: 10x Genomics' insider roster includes Bradford Crutchfield (Insider), Benjamin Hindson (Insider), Sridhar Kosaraju (Director), Mathai Mammen (Director), Alan Mateo (Director), Justin McAnear (CFO), Serge Saxonov (CEO), John Stuelpnagel (Director), Adam Taich (CFO), and James Wilbur (Insider). Learn More on 10x Genomics' active insiders.
Are insiders buying or selling shares of 10x Genomics?: During the last year, 10x Genomics insiders bought shares 1 times. They purchased a total of 40,000 shares worth more than $445,600.00. During the last year, insiders at the sold shares 11 times. They sold a total of 103,118 shares worth more than $1,455,301.86. The most recent insider tranaction occured on November, 24th when CFO Adam Taich sold 11,888 shares worth more than $225,872.00. Insiders at 10x Genomics own 9.4% of the company. Learn More about insider trades at 10x Genomics.
Information on this page was last updated on 11/24/2025.

Adam Taich Insider Trading History at 10x Genomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/24/2025	Sell	11,888	$19.00	$225,872.00	297,385
8/22/2025	Sell	22,315	$13.79	$307,723.85	309,273
5/22/2025	Sell	4,044	$8.30	$33,565.20	331,588

Adam Taich Buying and Selling Activity at 10x Genomics

10x Genomics Company Overview

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Today's Range

Now: $18.15

$17.06

$18.31

50 Day Range

MA: $14.46

$11.34

$20.13

2 Week Range

Now: $18.15

$6.78

$20.34

Volume

1,826,312 shs

Average Volume

3,283,431 shs

Market Capitalization

$2.30 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15